ClinicalTrials.gg
Enrolling by invitationNCT07310381Updated Nov 2, 2026

Vagus Nerve Stimulation (VNS) Electroencephalogram (EEG) Protocol Supplement

An interventional study of Vagus Nerve Stimulation in Treatment Resistant Depression, sponsored by Stanford University. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Stanford University · Not applicable, Interventional, and Other

How we know

Updated Nov 2, 2026Now Enrolling by invitationFirst site in United States+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies in Depressive Disorder, Treatment-Resistant by Stanford University — 2 open to participants now, 6 under way, none of them phase 3. Depressive Disorder, Treatment-Resistant · Stanford University.

Planned enrollment
10th of 12
12 · median 35
Started
2026
with 1 other
No phase
12 of 13
2 open now
Registered
12th of 13
by date

Among the 13 studies in Depressive Disorder, Treatment-Resistant by Stanford University, this one is the 10th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2026, is one of 12 with no phase, and was the 12th registered.

Depressive Disorder, Treatment-Resistant

450 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 148 are open to participants now.

Browse Depressive Disorder, Treatment-Resistant studies →

Open to participants now

2 of the 13 studies in Depressive Disorder, Treatment-Resistant by Stanford University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 115 Depressive Disorder, Treatment-Resistant studies recruiting now, 27 (23%) set no upper age limit and 76 (66%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Depressive Disorder, Treatment-Resistant by Stanford University, or all of them as a file.
02

Study summary

The study will examine the autonomic, physiologic and neurophysiologic effects of implanted Vagus Nerve Stimulation (VNS) in treatment-resistant depression patients.

Read the detailed description

The purpose of this study is to examine the autonomic and physiologic effects of implanted VNS in treatment-resistant depression patients. To examine the neurophysiologic effects of Vagus Nerve Stimulation (VNS) in treatment-resistant depression.

03

Conditions studied

  • Treatment Resistant Depression
04

Who can participate

The criteria were revised on the registry on Nov 2, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must be at least 18 years old.
  2. Participants must be able to read, understand and have the capacity to provide written and Health Insurance Portability and Accountability Act (HIPAA) authorization.
  3. Proficiency in English sufficient to complete questionnaire and follow instructions during fMRI assessments and iTBS interventions.
  4. Willingness to comply with all study procedures and the ability to communicate with study personnel about adverse events and other information
  5. Participant must be currently implanted with a VNS device for the clinical indication of Major Depressive Disorder (MDD)

    a. Clinical Indication of MDD as defined: Participant has a diagnosis of chronic (≥ 2 years) or ≥ 4 recurrent depressive episodes as defined by criteria documented using the MINI criteria and psychiatric medical record review.

  6. Access to ongoing psychiatric care before and after completion of the study.
  7. In good general health, as evidenced by medical history
  8. Agreement to adhere to Lifestyle Considerations throughout study duration.

Exclusion criteria

Exclusion Criteria:

  1. Participant does not speak or read English
  2. Any other clinical reasons deemed by the investigator of the study for which the participant would not be an appropriate candidate for the study.
  3. to EEG
  4. Medication Contraindications
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Other
    Participants implanted with VNS

    Participants receiving vagus nerve stimulation through an implanted Vagus Nerve Stimulation Device.

    Device: Vagus Nerve Stimulation

Interventions

  • DeviceVagus Nerve Stimulation

    Participants receiving vagus nerve stimulation through an implanted Vagus Nerve Stimulation Device.

06

What researchers measure

Primary outcomes

  1. Gamma and theta band phase-amplitude coupling

    Measurement of EEG and ECG to quantify changes in phase-amplitude coupling in the gamma and theta band related to chronic VNS

    Time frame: Baseline, Week 6 and Week 19

Secondary outcomes

  1. Heart brain coupling

    Measurement of heart brain coupling (heart rate entrainment in response to trains of intermittent theta burst stimulation) with VNS via an EKG sweep

    Time frame: Week 19

  2. Heart rate

    Measure heart rate and heart rate variability with VNS

    Time frame: Baseline, Week 6 and Week 19

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.

Of 136 non-industry interventional studies with no phase under Depressive Disorder, Treatment-Resistant, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 88. This study's planned 9 months is below that.

Counting every sponsor, half of 140 studies reached it within 50 months; a quarter within 22 and three quarters within 88.

Start moved once since we started tracking on Sep 25, 2026: Jan 2026 → Mar 2026, on Nov 2, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2025
First posted
Dec 30, 2025
StartActual
Mar 17, 2026was Jan 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Enrolling by invitation
changed Nov 2, 2026
Sites
1 site added — first site in United States
Show site
  • Department of Psychiatry and Behavioral Sciences, Stanford School of Medicine · Stanford, United States
Nov 2, 2026
Start date
Jan 1, 2026→Mar 17, 2026 (actual)
Nov 2, 2026
Eligibility
1 inclusion criterion edited, 1 removed; 2 exclusion criteria removed
What changed in the criteria
Inclusion criteria
  • EditedParticipant must be currently enrolled in the REVEAL study and implanted with a VNS device for the clinical indication of Major Depressive Disorder (MDD)
  • RemovedFor females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation.
Exclusion criteria
  • RemovedParticipant is pregnant
  • RemovedContraindication to MRI (ferromagnetic metal in their body)
Nov 2, 2026
Secondary outcomes
5 removed
What changed in the outcomes
  • RemovedResting state functional connectivity between the left dorsolateral prefrontal cortex and subgenual anterior cingulate cortexTime frame: Baseline, Week 6 and Week 19
  • Removedother outcomeGalvanic Skin ResponseTime frame: Baseline, Week 6 and Week 19
  • Removedother outcomeBlood pressureTime frame: Baseline, Week 6 and Week 19
  • Removedother outcomeRespiratory rateTime frame: Baseline, Week 6 and Week 19
  • Removedother outcomePupil diameterTime frame: Baseline, Week 6 and Week 19
Nov 2, 2026
Contact
No study contact listed any more: removed i•••@stanford.edu · •••6920; removed k•••@stanford.edu
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Not yet recruiting→Enrolling by invitation
    1 site added — first site in United States
    Show site
    • Department of Psychiatry and Behavioral Sciences, Stanford School of Medicine · Stanford, United States
    Start date Jan 1, 2026→Mar 17, 2026 (now actual)
    Eligibility 1 inclusion criterion edited, 1 removed; 2 exclusion criteria removed
    What changed in the criteria
    Inclusion criteria
    • EditedParticipant must be currently enrolled in the REVEAL study and implanted with a VNS device for the clinical indication of Major Depressive Disorder (MDD)
    • RemovedFor females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation.
    Exclusion criteria
    • RemovedParticipant is pregnant
    • RemovedContraindication to MRI (ferromagnetic metal in their body)
    Secondary outcomes 5 removed
    What changed in the outcomes
    • RemovedResting state functional connectivity between the left dorsolateral prefrontal cortex and subgenual anterior cingulate cortexTime frame: Baseline, Week 6 and Week 19
    • Removedother outcomeGalvanic Skin ResponseTime frame: Baseline, Week 6 and Week 19
    • Removedother outcomeBlood pressureTime frame: Baseline, Week 6 and Week 19
    • Removedother outcomeRespiratory rateTime frame: Baseline, Week 6 and Week 19
    • Removedother outcomePupil diameterTime frame: Baseline, Week 6 and Week 19
    Contact No study contact listed any more: removed i•••@stanford.edu · •••6920; removed k•••@stanford.edu
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07310381
Responsible party
Christopher Wallace Austelle (Clinical Assistant Professor, Department of Psychiatry & Behavioral Sciences, Stanford University School of Medicine, Stanford University) — Principal investigator
First posted
Dec 30, 2025
Start date
Mar 17, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 2, 2026

Study contacts

Christopher Austelle, MD
study director · Department of Psychiatry and Behavioral Sciences, Stanford School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion